›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TheraPrint® test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AgendiaType:
Laboratory Developed Test
Related tests:
TheraPrint is a microarray-based gene expression panel of 125 genes identified as potential targets for prognosis and therapeutic response. These genes may hold the key to a greater level of personalized prognosis and therapy for BC pts. It provides an individualized genomic fingerprint of the patient’s tumor and correlates the results with a likely response to a variety of hormonal, chemo and biological therapies.
Cancer:
Breast Cancer
Gene:
BCL2 (B-cell CLL/lymphoma 2), BRAF (B-raf proto-oncogene), CCND1 (Cyclin D1), EGFR (Epidermal growth factor receptor), EPHA2 (EPH receptor A2), ERBB4 (erb-b2 receptor tyrosine kinase 4)
See More ...
BCL2 (B-cell CLL/lymphoma 2), BRAF (B-raf proto-oncogene), CCND1 (Cyclin D1), EGFR (Epidermal growth factor receptor), EPHA2 (EPH receptor A2), ERBB4 (erb-b2 receptor tyrosine kinase 4), HIF1A (Hypoxia inducible factor 1, alpha subunit), KRAS (KRAS proto-oncogene GTPase), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), TIMP1 (Tissue inhibitor of metalloproteinases 1), TOP2A (DNA topoisomerase 2-alpha)
Method:
Immunohistochemistry (IHC)
